The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Understanding & Treating Neonatal Lupus

Understanding & Treating Neonatal Lupus

June 21, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
CHAINFOTO24 / shutterstock.com

CHAINFOTO24 / shutterstock.com

CHICAGO—Neonatal lupus is a rare disorder, but its onset can be dramatic, and it can be fatal. Clinicians must be armed with information to manage it and help guide parents through difficult decisions, an expert said in April at the State-of-the-Art Clinical Symposium.

You Might Also Like
  • Autoantibodies in Pregnant Woman May Put Infant at Risk for Neonatal Lupus Erythematosus
  • Treating Lupus: Strategies, Treat to Target & Biologics
  • FOCIS 2015: Research Increases Understanding of Lupus, RA
Explore This Issue
June 2018
Also By This Author
  • Immune System Targeted for Research into New Rheumatoid Arthritis Treatments

Despite the name, neonatal lupus does not mean that either the mother or the unborn child has systemic lupus erythematosus, said Jill Buyon, MD, professor of rheumatology at New York University Langone School of Medicine. In this disease, anti-Ro or anti-La antibodies, and sometimes both, cross the placenta at about 11 weeks of gestation by way of the neonatal FC receptor (FcRn), resulting in congenital heart block (CHB) or a neonatal rash in 2% of fetuses when the mother has not previously had an affected child.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A slow fetal heartbeat, especially between 18 and 26 weeks of gestation, is a warning sign, Dr. Buyon said.

“The finding of a low heartbeat in a fetus, even in a totally healthy mother, should always prompt testing for anti-Ro antibodies,” she said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Rash

The risk of skin rash in neonatal lupus is about 7–16%. The rash can be detected at birth, but it is usually detected a few weeks after birth upon exposure to ultraviolet light. Children with neonatal lupus should be protected from the sun. The rash, which resembles subacute cutaneous lupus, lasts about 17 weeks, and only rarely results in scarring.1

The disease can become devastating in a hurry. A fetus can go from having a normal sinus rhythm to complete & irreversible heart block & death in seven or fewer days, Dr. Buyon said.

Congenital Heart Block

The bigger concern with neonatal lupus is CHB. When isolated CHB is found at 18–26 weeks of gestation, more than 85% of mothers will have anti-Ro antibodies. When a mother has anti-Ro antibodies, with no prior children affected by CHB or rash, a 2% chance exists that the fetus will have CHB, Dr. Buyon said. The recurrence rate of CHB is 18%. The mother’s heart is not affected, she said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The disease can become devastating in a hurry. A fetus can go from having a normal sinus rhythm to complete and irreversible heart block and death in seven or fewer days, Dr. Buyon said.

Research on the disease is a challenge because it’s rare and because of the complex interplay of genetics and environment—the presence of antibodies is just part of the picture. But a proposed model is that the antibodies interrupt the normal remodeling process of the heart, setting off an inflammatory process that leads to fibrosis.

Pages: 1 2 | Single Page

Filed Under: SLE (Lupus) Tagged With: Neonatal lupus erythematosusIssue: June 2018

You Might Also Like:
  • Autoantibodies in Pregnant Woman May Put Infant at Risk for Neonatal Lupus Erythematosus
  • Treating Lupus: Strategies, Treat to Target & Biologics
  • FOCIS 2015: Research Increases Understanding of Lupus, RA
  • Reflections on Living with Lupus, and on Treating It

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)